Bayer/Onyx’s Nexavar Proves Hard To Topple In Liver Cancer
This article was originally published in The Pink Sheet Daily
A study of sorafenib in combination with Astellas/Genentech’s Tarceva showed that in hepatocellular carcinoma, two targeted therapies are not better than sorafenib alone. These results, coupled with the failure of Bristol-Myers Squibb’s brivanib to demonstrate non-inferiority, reaffirm Nexavar’s place in first-line treatment and have analysts looking ahead to new indications.
You may also be interested in...
FDA Cancer Center’s New ‘Projects’ Focus On Early Endpoints; Asian American, Native Hawaiian Populations
Launched in 2023, Project Endpoint focuses on advancing understanding of early, novel endpoints, while Project ASIATICA aims to bring greater awareness of challenges and health disparities faced by Asian American, Native Hawaiian, and Other Pacific Islander patients with cancer.
BMS CEO Boerner acknowledged the complexity of patient assistance programs, and the need for simplification, during a Senate hearing. CEOs of J&J and Merck also tout their patient assistance programs as showing the firms’ commitment to helping patients access drugs they cannot afford.
Despite objecting to Democrats’ reasons for hauling three pharma CEOs in front of the Senate Health Committee, Ranking Member Bill Cassidy pressed the execs on anticompetitive tactics on biosimilars and how to keep gene therapies from bankrupting state Medicaid programs.